Intracept Minimally-invasive PROcedure for VErtebrogenic Back Pain
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorBoston Scientific Corporation
About this trial
Compile real-world outcomes of commercially approved Intracept™ Intraosseous Nerve Ablation Systems in the treatment of patients diagnosed with vertebrogenic pain.
Eligibility criteria
Qualifiers
Study candidate is scheduled to be treated with a commercially approved Intracept™ Intraosseous Nerve Ablation System per local Instructions for Use (IFU).
Signed a valid, IRB/EC-approved informed consent form.
Disqualifiers
Meets any contraindications per locally applicable Instructions for Use (IFU).
Trial design
Treatments tested in this trial
- Intracept™ Intraosseous Nerve Ablation
Treatment groups
1,500 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov